New virus combo tackles liver metastases in colorectal cancer
NCT ID NCT06283134
First seen Jan 10, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This early-stage trial tests a new approach for people with colorectal cancer that has spread to the liver and hasn't responded to standard treatments. It combines a virus designed to attack cancer cells (BioTTT001) with two drugs (toripalimab and regorafenib). The study will enroll 60 participants to check safety and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oncolytic adenovirus (BioTTT001) plus toripalimab and regorafenib
What this could lead to
If successful, this could point toward a new combination treatment for colorectal cancer that has spread to the liver, potentially improving survival.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so safety and dosing are still being explored. The treatment may not work or could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.